Semler Scientific (SMLR) Financials

$26.33 -0.47 (-1.75%)

Closing price 10/13/2025 04:00 PM Eastern

Extended Trading

$25.10 -1.23 (-4.67%)

As of 08:44 AM Eastern

Annual Income Statements for Semler Scientific

This table shows Semler Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	14	21	41
Consolidated Net Income / (Loss)	14	21	41
Net Income / (Loss) Continuing Operations	14	21	41
Total Pre-Tax Income	18	24	48
Total Operating Income	17	22	21
Total Gross Profit	52	61	52
Total Revenue	57	68	56
Operating Revenue	57	68	56
Total Cost of Revenue	4.25	6.98	4.76
Operating Cost of Revenue	4.25	6.98	4.76
Total Operating Expenses	35	39	31
Selling, General & Admin Expense	13	14	13
Marketing Expense	18	18	13
Research & Development Expense	4.81	5.77	4.79
Restructuring Charge	0.00	0.73	0.00
Total Other Income / (Expense), net	0.49	1.84	27
Interest & Investment Income	0.49	2.47	1.88
Other Income / (Expense), net	-0.01	-0.63	25
Income Tax Expense	3.37	3.52	6.99
Basic Earnings per Share	$2.13	$3.06	$5.66
Weighted Average Basic Shares Outstanding	6.73M	6.73M	7.23M
Diluted Earnings per Share	$1.79	$2.63	$5.13
Weighted Average Diluted Shares Outstanding	8.00M	7.82M	7.98M
Weighted Average Basic & Diluted Shares Outstanding	6.84M	7.03M	9.60M

This table shows Semler Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	3.68	3.22	4.97	5.88	5.51	4.22	6.07	0.01	5.61	29
Consolidated Net Income / (Loss)	3.68	3.22	4.97	5.88	5.51	4.22	6.07	0.01	5.61	29
Net Income / (Loss) Continuing Operations	3.68	3.22	4.97	5.88	5.51	4.22	6.07	0.01	5.61	29
Total Pre-Tax Income	4.60	3.96	6.63	7.67	6.99	2.81	7.80	1.14	6.38	33
Total Operating Income	4.47	3.62	6.26	7.18	6.30	2.52	6.98	5.35	5.07	3.54
Total Gross Profit	13	13	17	17	15	12	15	13	12	11
Total Revenue	14	14	18	19	16	15	16	14	14	12
Operating Revenue	14	14	18	19	16	15	16	14	14	12
Total Cost of Revenue	1.14	1.18	1.27	1.22	1.11	3.39	1.25	1.26	1.16	1.10
Operating Cost of Revenue	1.14	1.18	1.27	1.22	1.11	3.39	1.25	1.26	1.16	1.10
Total Operating Expenses	8.44	9.00	11	10	8.91	9.15	7.68	7.86	7.29	7.77
Selling, General & Admin Expense	3.05	2.98	3.86	3.46	3.71	3.26	2.87	2.96	3.13	3.77
Marketing Expense	4.15	4.66	5.19	4.99	3.42	4.55	3.68	3.46	2.98	2.97
Research & Development Expense	1.24	1.37	1.63	1.76	1.17	1.21	1.14	1.44	1.19	1.03
Total Other Income / (Expense), net	0.13	0.34	0.38	0.49	0.69	0.29	0.82	-4.21	1.31	29
Interest & Investment Income	-	-	0.48	0.60	0.69	0.70	0.82	0.71	0.17	0.18
Other Income / (Expense), net	-0.00	-0.00	-0.11	-0.11	-0.00	-0.41	0.00	-4.93	1.14	29
Income Tax Expense	0.93	0.74	1.66	1.79	1.47	-1.41	1.72	1.13	0.77	3.37
Basic Earnings per Share	$0.55	$0.48	$0.74	$0.88	$0.82	$0.62	$0.88	$0.00	$0.80	$3.98
Weighted Average Basic Shares Outstanding	6.68M	6.73M	6.70M	6.71M	6.72M	6.73M	6.89M	6.94M	7.05M	7.23M
Diluted Earnings per Share	$0.46	$0.41	$0.63	$0.75	$0.71	$0.54	$0.78	$0.00	$0.72	$3.63
Weighted Average Diluted Shares Outstanding	7.94M	8.00M	7.90M	7.87M	7.82M	7.82M	7.78M	7.80M	7.77M	7.98M
Weighted Average Basic & Diluted Shares Outstanding	6.84M	6.84M	6.85M	6.86M	6.87M	7.03M	7.07M	7.13M	7.27M	9.60M

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-14	34	-48
Net Cash From Operating Activities	17	21	24
Net Cash From Continuing Operating Activities	17	21	24
Net Income / (Loss) Continuing Operations	14	21	41
Consolidated Net Income / (Loss)	14	21	41
Depreciation Expense	0.59	0.60	0.58
Non-Cash Adjustments To Reconcile Net Income	1.23	4.55	-24
Changes in Operating Assets and Liabilities, net	1.32	-4.40	6.92
Net Cash From Investing Activities	-27	18	-190
Net Cash From Continuing Investing Activities	-27	18	-190
Purchase of Property, Plant & Equipment	-2.16	-0.35	-0.05
Purchase of Investments	-20	-59	-0.50
Sale and/or Maturity of Investments	-4.68	78	0.00
Other Investing Activities, net	0.00	-0.48	-189
Net Cash From Financing Activities	-4.94	-5.41	117
Net Cash From Continuing Financing Activities	-4.94	-5.41	117
Repurchase of Common Equity	-4.99	-1.95	-3.00
Issuance of Common Equity	-	0.00	120
Other Financing Activities, net	0.05	-3.46	0.59
Cash Income Taxes Paid	2.40	4.06	2.26

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	5.51	-23	-18	34	-2.00	20	5.55	-55	-0.76	2.25
Net Cash From Operating Activities	8.02	1.71	0.86	11	4.83	4.44	5.62	4.93	6.43	7.43
Net Cash From Continuing Operating Activities	8.02	1.71	0.86	11	4.83	4.44	5.62	4.93	6.43	7.43
Net Income / (Loss) Continuing Operations	3.68	3.22	4.97	5.88	5.51	4.22	6.07	0.01	5.61	29
Consolidated Net Income / (Loss)	3.68	3.22	4.97	5.88	5.51	4.22	6.07	0.01	5.61	29
Depreciation Expense	0.15	0.13	0.13	0.15	0.16	0.16	0.18	0.17	0.13	0.10
Non-Cash Adjustments To Reconcile Net Income	0.14	0.17	0.63	0.42	0.50	3.00	0.16	5.34	-0.91	-29
Changes in Operating Assets and Liabilities, net	4.06	-1.80	-4.87	4.75	-1.34	-2.94	-0.79	-0.58	1.59	6.70
Net Cash From Investing Activities	-0.49	-24	-18	25	-6.78	19	-0.08	-60	-8.44	-121
Net Cash From Continuing Investing Activities	-0.49	-24	-18	25	-6.78	19	-0.08	-60	-8.44	-121
Purchase of Property, Plant & Equipment	-0.49	-0.81	-0.64	-0.30	-0.15	0.74	-0.08	0.03	-0.04	0.03
Other Investing Activities, net	-	-	-	-	-	-0.48	-	-	-8.40	-121
Net Cash From Financing Activities	-2.03	0.08	-0.15	-1.98	-0.05	-3.24	0.01	0.11	1.25	116
Net Cash From Continuing Financing Activities	-2.03	0.08	-0.15	-1.98	-0.05	-3.24	0.01	0.11	1.25	116
Repurchase of Common Equity	-2.05	-	-	-	-	-	-	-	-0.49	-2.41
Issuance of Common Equity	-	-	-	-	-	-	-	-	-	117
Other Financing Activities, net	0.02	0.08	-0.15	-0.03	-0.05	-3.24	0.01	0.21	-0.80	1.17

This table presents Semler Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	63	78	240
Total Current Assets	49	66	23
Cash & Equivalents	23	57	8.82
Restricted Cash	0.00	0.13	0.13
Note & Lease Receivable	-	0.00	6.10
Accounts Receivable	3.88	6.13	4.38
Inventories, net	0.47	0.45	0.36
Prepaid Expenses	1.47	2.04	2.90
Plant, Property, & Equipment, net	2.48	3.01	1.91
Total Noncurrent Assets	11	9.12	215
Long-Term Investments	0.82	0.51	0.51
Noncurrent Note & Lease Receivables	4.68	5.37	0.00
Intangible Assets	-	0.00	215
Noncurrent Deferred & Refundable Income Taxes	2.30	2.96	0.00
Other Noncurrent Operating Assets	3.51	0.27	0.09
Total Liabilities & Shareholders' Equity	63	78	240
Total Liabilities	7.02	6.27	9.08
Total Current Liabilities	6.86	6.20	6.31
Accounts Payable	0.84	0.40	0.14
Accrued Expenses	4.75	4.50	5.17
Current Deferred Revenue	1.16	1.12	0.77
Other Current Liabilities	0.11	0.18	0.23
Total Noncurrent Liabilities	0.16	0.07	2.77
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	2.77
Other Noncurrent Operating Liabilities	0.16	0.07	0.00
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	56	72	231
Total Preferred & Common Equity	56	72	231
Total Common Equity	56	72	231
Common Stock	16	12	130
Retained Earnings	39	60	101

This table presents Semler Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	61	70	75	79	84	85	92
Total Current Assets	52	56	61	64	72	24	21
Cash & Equivalents	46	5.31	39	37	63	7.33	6.57
Restricted Cash	-	-	-	-	0.13	0.13	0.13
Note & Lease Receivable	-	-	-	-	-	6.10	6.10
Accounts Receivable	3.67	9.34	6.03	5.97	6.13	7.47	6.67
Inventories, net	0.51	0.51	0.48	0.44	0.41	0.39	0.38
Prepaid Expenses	1.96	2.77	2.42	1.95	2.48	2.27	1.65
Plant, Property, & Equipment, net	2.62	3.58	3.69	3.26	0.00	2.39	1.74
Total Noncurrent Assets	6.62	11	11	12	11	59	69
Long-Term Investments	0.82	0.82	0.82	0.82	0.51	0.51	0.51
Noncurrent Note & Lease Receivables	1.18	5.07	4.96	5.46	7.44	0.00	0.00
Intangible Assets	-	-	-	-	-	55	64
Noncurrent Deferred & Refundable Income Taxes	2.35	2.38	2.51	2.78	3.10	3.12	3.32
Other Noncurrent Operating Assets	2.27	2.82	2.74	2.74	0.25	0.13	0.65
Total Liabilities & Shareholders' Equity	61	70	75	79	84	85	92
Total Liabilities	8.57	9.06	10	8.67	5.95	6.39	6.84
Total Current Liabilities	8.39	8.92	10	8.58	5.90	6.36	6.84
Accounts Payable	0.48	0.30	0.51	0.30	0.41	0.23	0.55
Accrued Expenses	6.65	7.21	8.24	7.00	4.31	5.09	5.26
Current Deferred Revenue	1.16	1.29	1.19	1.12	1.00	0.84	0.81
Other Current Liabilities	0.09	0.13	0.14	0.16	0.19	0.21	0.23
Total Noncurrent Liabilities	0.18	0.14	0.12	0.09	0.05	0.02	0.00
Other Noncurrent Operating Liabilities	0.18	0.14	0.12	0.09	0.05	0.02	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	52	61	65	71	78	78	85
Total Preferred & Common Equity	52	61	65	71	78	78	85
Total Common Equity	52	61	65	71	78	78	85
Common Stock	16	17	15	15	12	13	14
Retained Earnings	36	44	50	56	66	66	71

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	6.90%	20.28%	-17.44%
EBITDA Growth	-11.39%	24.97%	109.58%
EBIT Growth	-11.56%	25.76%	112.71%
NOPAT Growth	-19.08%	36.46%	-5.94%
Net Income Growth	-16.82%	43.69%	98.70%
EPS Growth	-15.57%	46.93%	95.06%
Operating Cash Flow Growth	8.76%	22.14%	14.44%
Free Cash Flow Firm Growth	-33.92%	75.92%	-1,226.03%
Invested Capital Growth	58.96%	18.55%	1,486.17%
Revenue Q/Q Growth	4.14%	1.89%	-4.48%
EBITDA Q/Q Growth	11.81%	-6.19%	184.70%
EBIT Q/Q Growth	12.49%	-6.48%	192.61%
NOPAT Q/Q Growth	11.45%	4.96%	2.25%
Net Income Q/Q Growth	13.55%	5.13%	157.00%
EPS Q/Q Growth	14.74%	5.20%	151.47%
Operating Cash Flow Q/Q Growth	0.30%	14.69%	13.93%
Free Cash Flow Firm Q/Q Growth	-30.53%	65.28%	-305.42%
Invested Capital Q/Q Growth	96.30%	0.19%	183.18%
Profitability Metrics	-	-	-
Gross Margin	92.50%	89.76%	91.55%
EBITDA Margin	31.38%	32.60%	82.75%
Operating Margin	30.35%	32.64%	37.19%
EBIT Margin	30.34%	31.72%	81.73%
Profit (Net Income) Margin	25.27%	30.19%	72.65%
Tax Burden Percent	80.97%	85.41%	85.41%
Interest Burden Percent	102.87%	111.42%	104.08%
Effective Tax Rate	19.03%	14.59%	14.59%
Return on Invested Capital (ROIC)	145.31%	147.81%	15.20%
ROIC Less NNEP Spread (ROIC-NNEP)	144.35%	144.72%	-53.20%
Return on Net Nonoperating Assets (RNNOA)	-117.01%	-115.52%	11.84%
Return on Equity (ROE)	28.30%	32.29%	27.04%
Cash Return on Invested Capital (CROIC)	99.78%	130.84%	-161.08%
Operating Return on Assets (OROA)	30.34%	30.73%	28.95%
Return on Assets (ROA)	25.27%	29.25%	25.73%
Return on Common Equity (ROCE)	28.30%	32.29%	27.04%
Return on Equity Simple (ROE_SIMPLE)	25.73%	28.67%	17.72%
Net Operating Profit after Tax (NOPAT)	14	19	18
NOPAT Margin	24.57%	27.88%	31.76%
Net Nonoperating Expense Percent (NNEP)	0.97%	3.10%	68.40%
Return On Investment Capital (ROIC_SIMPLE)	-	26.48%	7.75%
Cost of Revenue to Revenue	7.50%	10.24%	8.45%
SG&A Expenses to Revenue	22.47%	20.96%	22.62%
R&D to Revenue	8.48%	8.47%	8.51%
Operating Expenses to Revenue	62.15%	57.12%	54.36%
Earnings before Interest and Taxes (EBIT)	17	22	46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	22	47
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.05	4.24	1.70
Price to Tangible Book Value (P/TBV)	4.05	4.24	24.35
Price to Revenue (P/Rev)	3.98	4.46	6.97
Price to Earnings (P/E)	15.76	14.79	9.59
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	6.35%	6.76%	10.42%
Enterprise Value to Invested Capital (EV/IC)	15.45	17.67	1.73
Enterprise Value to Revenue (EV/Rev)	3.21	3.62	6.80
Enterprise Value to EBITDA (EV/EBITDA)	10.22	11.09	8.22
Enterprise Value to EBIT (EV/EBIT)	10.57	11.40	8.32
Enterprise Value to NOPAT (EV/NOPAT)	13.05	12.97	21.42
Enterprise Value to Operating Cash Flow (EV/OCF)	10.41	11.56	15.69
Enterprise Value to Free Cash Flow (EV/FCFF)	19.01	14.65	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.81	-0.80	-0.22
Leverage Ratio	1.12	1.10	1.05
Compound Leverage Factor	1.15	1.23	1.09
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	22.79	32.91	27.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.13	10.64	3.59
Quick Ratio	6.85	10.21	3.06
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	9.56	17	-189
Operating Cash Flow to CapEx	808.47%	6,182.61%	47,862.75%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	1.00	0.97	0.35
Accounts Receivable Turnover	15.11	13.62	10.72
Inventory Turnover	8.35	15.28	11.85
Fixed Asset Turnover	25.11	24.87	22.91
Accounts Payable Turnover	6.65	11.29	17.56
Days Sales Outstanding (DSO)	24.16	26.79	34.05
Days Inventory Outstanding (DIO)	43.74	23.88	30.79
Days Payable Outstanding (DPO)	54.85	32.32	20.78
Cash Conversion Cycle (CCC)	13.04	18.35	44.06
Capital & Investment Metrics	-	-	-
Invested Capital	12	14	221
Invested Capital Turnover	5.91	5.30	0.48
Increase / (Decrease) in Invested Capital	4.37	2.18	207
Enterprise Value (EV)	182	247	383
Market Capitalization	226	304	392
Book Value per Share	$8.14	$10.45	$31.76
Tangible Book Value per Share	$8.14	$10.45	$2.22
Total Capital	56	72	231
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-44	-58	-9.46
Capital Expenditures (CapEx)	2.16	0.35	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.04	2.41	7.42
Debt-free Net Working Capital (DFNWC)	42	60	16
Net Working Capital (NWC)	42	60	16
Net Nonoperating Expense (NNE)	-0.40	-1.57	-23
Net Nonoperating Obligations (NNO)	-44	-58	-9.46
Total Depreciation and Amortization (D&A)	0.59	0.60	0.58
Debt-free, Cash-free Net Working Capital to Revenue	-1.83%	3.54%	13.19%
Debt-free Net Working Capital to Revenue	74.18%	87.62%	29.09%
Net Working Capital to Revenue	74.18%	87.62%	29.09%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$2.13	$3.06	$5.66
Adjusted Weighted Average Basic Shares Outstanding	6.73M	6.73M	7.23M
Adjusted Diluted Earnings per Share	$1.79	$2.63	$5.13
Adjusted Weighted Average Diluted Shares Outstanding	8.00M	7.82M	7.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.84M	7.03M	9.60M
Normalized Net Operating Profit after Tax (NOPAT)	14	20	18
Normalized NOPAT Margin	24.57%	28.80%	31.76%
Pre Tax Income Margin	31.21%	35.35%	85.06%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	34.84%	9.47%	7.34%

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.40%	19.52%	29.89%	25.47%	16.15%	9.15%	-12.65%	-22.25%	-17.19%	-17.55%
EBITDA Growth	-14.72%	100.91%	53.23%	35.39%	39.83%	-39.19%	13.95%	-91.79%	-1.78%	1,328.48%
EBIT Growth	-15.04%	112.09%	55.99%	36.52%	41.04%	-41.48%	13.48%	-94.02%	-1.41%	1,431.87%
NOPAT Growth	-13.96%	94.56%	39.52%	35.50%	39.30%	28.72%	15.94%	-99.06%	-10.34%	-16.05%
Net Income Growth	-11.45%	113.40%	47.89%	44.31%	50.04%	31.25%	22.22%	-99.81%	1.72%	591.92%
EPS Growth	-9.80%	127.78%	53.66%	47.06%	54.35%	31.71%	23.81%	-100.00%	1.41%	572.22%
Operating Cash Flow Growth	5.03%	3.20%	-42.68%	79.71%	-39.77%	159.77%	553.19%	-55.93%	33.00%	67.20%
Free Cash Flow Firm Growth	125.79%	-16.00%	-146.49%	-42.66%	-161.20%	212.18%	448.26%	-2,233.25%	-1,919.17%	-12,861.20%
Invested Capital Growth	-17.46%	58.96%	71.63%	28.51%	132.28%	18.55%	-20.41%	458.15%	461.16%	1,486.17%
Revenue Q/Q Growth	-5.27%	-1.79%	31.98%	2.19%	-12.30%	-7.72%	5.62%	-9.04%	-6.59%	-8.13%
EBITDA Q/Q Growth	-13.41%	-18.97%	67.82%	14.99%	-10.57%	-64.76%	214.46%	-91.71%	969.31%	412.51%
EBIT Q/Q Growth	-13.79%	-19.04%	70.14%	14.96%	-10.94%	-66.41%	229.93%	-93.94%	1,367.38%	421.98%
NOPAT Q/Q Growth	-12.20%	-17.63%	59.47%	17.49%	-9.73%	-23.89%	43.64%	-99.05%	8,509.91%	-28.74%
Net Income Q/Q Growth	-9.79%	-12.49%	54.51%	18.31%	-6.21%	-23.45%	43.88%	-99.82%	50,890.91%	420.70%
EPS Q/Q Growth	-9.80%	-10.87%	53.66%	19.05%	-5.33%	-23.94%	44.44%	-100.00%	0.00%	404.17%
Operating Cash Flow Q/Q Growth	28.75%	-78.68%	-49.65%	1,200.35%	-56.85%	-8.05%	26.61%	-12.27%	30.22%	15.60%
Free Cash Flow Firm Q/Q Growth	2.42%	-129.49%	-80.94%	204.92%	-209.32%	154.05%	461.71%	-742.66%	-3.48%	-241.63%
Invested Capital Q/Q Growth	-38.94%	96.30%	47.96%	-27.54%	10.37%	0.19%	-0.66%	408.13%	10.96%	183.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.90%	91.44%	93.03%	93.45%	93.19%	77.52%	92.16%	91.32%	91.44%	91.13%
EBITDA Margin	32.87%	27.12%	34.48%	38.80%	39.57%	15.11%	44.99%	4.10%	46.93%	261.79%
Operating Margin	31.80%	26.21%	34.36%	38.59%	38.61%	16.74%	43.87%	36.99%	37.49%	28.53%
EBIT Margin	31.78%	26.20%	33.77%	38.00%	38.59%	14.05%	43.88%	2.92%	45.94%	260.99%
Profit (Net Income) Margin	26.16%	23.31%	27.29%	31.60%	33.80%	28.03%	38.19%	0.08%	41.51%	235.27%
Tax Burden Percent	79.87%	81.27%	74.91%	76.69%	78.91%	150.05%	77.89%	0.97%	87.98%	89.66%
Interest Burden Percent	103.07%	109.49%	107.87%	108.45%	110.99%	133.00%	111.74%	268.79%	102.71%	100.54%
Effective Tax Rate	20.13%	18.73%	25.09%	23.31%	21.09%	-50.05%	22.11%	99.03%	12.02%	10.34%
Return on Invested Capital (ROIC)	208.57%	125.98%	113.73%	170.58%	204.68%	133.21%	143.96%	0.53%	42.23%	12.24%
ROIC Less NNEP Spread (ROIC-NNEP)	208.31%	125.31%	113.05%	169.78%	203.63%	132.35%	142.78%	0.67%	38.63%	-65.10%
Return on Net Nonoperating Assets (RNNOA)	-179.65%	-101.58%	-84.88%	-136.93%	-170.68%	-105.65%	-110.68%	-0.28%	-15.85%	14.48%
Return on Equity (ROE)	28.92%	24.41%	28.85%	33.65%	34.00%	27.56%	33.28%	0.25%	26.38%	26.73%
Cash Return on Invested Capital (CROIC)	207.67%	99.78%	57.99%	123.93%	102.21%	130.84%	148.87%	-96.22%	-101.52%	-161.08%
Operating Return on Assets (OROA)	30.92%	26.20%	32.72%	36.91%	36.80%	13.61%	37.51%	2.25%	31.55%	92.43%
Return on Assets (ROA)	25.45%	23.31%	26.44%	30.70%	32.23%	27.16%	32.65%	0.06%	28.51%	83.32%
Return on Common Equity (ROCE)	28.92%	24.41%	28.85%	33.65%	34.00%	27.56%	33.28%	0.25%	26.38%	26.73%
Return on Equity Simple (ROE_SIMPLE)	24.10%	0.00%	26.04%	27.18%	27.66%	0.00%	27.84%	20.18%	18.64%	0.00%
Net Operating Profit after Tax (NOPAT)	3.57	2.94	4.69	5.51	4.97	3.78	5.43	0.05	4.46	3.18
NOPAT Margin	25.40%	21.30%	25.74%	29.60%	30.46%	25.12%	34.17%	0.36%	32.98%	25.58%
Net Nonoperating Expense Percent (NNEP)	0.26%	0.68%	0.68%	0.80%	1.05%	0.86%	1.19%	-0.13%	3.60%	77.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	5.27%	-	-	-	1.38%
Cost of Revenue to Revenue	8.10%	8.56%	6.97%	6.55%	6.81%	22.48%	7.84%	8.68%	8.56%	8.87%
SG&A Expenses to Revenue	21.68%	21.59%	21.20%	18.59%	22.74%	21.66%	18.03%	20.49%	23.16%	30.39%
R&D to Revenue	8.86%	9.89%	8.95%	9.47%	7.20%	8.02%	7.16%	9.96%	8.78%	8.28%
Operating Expenses to Revenue	60.10%	65.23%	58.67%	54.86%	54.58%	60.78%	48.29%	54.34%	53.96%	62.60%
Earnings before Interest and Taxes (EBIT)	4.46	3.61	6.15	7.07	6.30	2.12	6.98	0.42	6.21	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.62	3.74	6.28	7.22	6.46	2.28	7.15	0.59	6.34	32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.88	4.05	3.00	2.75	2.46	4.24	2.64	3.10	1.97	1.70
Price to Tangible Book Value (P/TBV)	4.88	4.05	3.00	2.75	2.46	4.24	2.64	10.36	8.05	24.35
Price to Revenue (P/Rev)	4.69	3.98	3.01	2.78	2.60	4.46	3.12	3.94	2.85	6.97
Price to Earnings (P/E)	20.24	15.76	11.51	10.13	8.88	14.79	9.47	15.37	10.56	9.59
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.94%	6.35%	8.69%	9.87%	11.26%	6.76%	10.56%	6.51%	9.47%	10.42%
Enterprise Value to Invested Capital (EV/IC)	34.86	15.45	8.02	10.08	8.41	17.67	10.24	3.34	2.06	1.73
Enterprise Value to Revenue (EV/Rev)	3.84	3.21	2.29	1.97	1.75	3.62	2.16	3.81	2.73	6.80
Enterprise Value to EBITDA (EV/EBITDA)	13.14	10.22	6.99	5.82	4.94	11.09	6.15	14.27	9.83	8.22
Enterprise Value to EBIT (EV/EBIT)	13.67	10.57	7.20	5.97	5.06	11.40	6.32	14.87	10.23	8.32
Enterprise Value to NOPAT (EV/NOPAT)	16.72	13.05	9.15	7.61	6.47	12.97	7.20	13.17	9.20	21.42
Enterprise Value to Operating Cash Flow (EV/OCF)	12.00	10.41	8.30	5.84	6.30	11.56	5.44	11.85	7.50	15.69
Enterprise Value to Free Cash Flow (EV/FCFF)	15.18	19.01	17.48	9.15	11.50	14.65	6.10	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.86	-0.81	-0.75	-0.81	-0.84	-0.80	-0.78	-0.42	-0.41	-0.22
Leverage Ratio	1.16	1.12	1.14	1.15	1.14	1.10	1.11	1.12	1.10	1.05
Compound Leverage Factor	1.20	1.23	1.23	1.25	1.27	1.47	1.24	3.00	1.13	1.06
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	20.70	22.08	14.99	13.48	14.96	32.08	23.82	24.91	16.88	27.28
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.16	7.13	6.23	6.03	7.51	10.64	12.18	3.72	3.14	3.59
Quick Ratio	5.87	6.85	5.87	5.74	7.23	10.21	11.67	3.28	2.83	3.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4.84	-1.43	-2.58	2.71	-2.96	1.60	8.99	-58	-60	-204
Operating Cash Flow to CapEx	1,633.60%	210.85%	134.74%	3,795.25%	3,242.28%	0.00%	6,943.21%	0.00%	18,357.14%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.97	1.00	0.97	0.97	0.95	0.97	0.86	0.77	0.69	0.35
Accounts Receivable Turnover	14.24	15.11	8.25	11.17	13.89	13.62	8.51	9.15	9.33	10.72
Inventory Turnover	4.56	8.35	8.22	9.61	10.06	15.28	15.13	16.26	17.20	11.85
Fixed Asset Turnover	36.20	25.11	21.59	23.50	22.75	24.87	0.00	20.33	23.57	22.91
Accounts Payable Turnover	11.85	6.65	13.52	9.89	12.21	11.29	19.67	19.02	16.67	17.56
Days Sales Outstanding (DSO)	25.63	24.16	44.25	32.68	26.29	26.79	42.87	39.91	39.12	34.05
Days Inventory Outstanding (DIO)	80.13	43.74	44.39	37.97	36.27	23.88	24.12	22.45	21.22	30.79
Days Payable Outstanding (DPO)	30.81	54.85	26.99	36.90	29.89	32.32	18.56	19.19	21.90	20.78
Cash Conversion Cycle (CCC)	74.95	13.04	61.65	33.74	32.66	18.35	48.43	43.17	38.44	44.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	6.00	12	17	13	14	14	14	70	78	221
Invested Capital Turnover	8.21	5.91	4.42	5.76	6.72	5.30	4.21	1.49	1.28	0.48
Increase / (Decrease) in Invested Capital	-1.27	4.37	7.27	2.80	7.93	2.18	-3.55	58	64	207
Enterprise Value (EV)	209	182	140	127	117	247	142	235	161	383
Market Capitalization	255	226	183	180	174	304	205	243	168	392
Book Value per Share	$7.70	$8.14	$8.94	$9.53	$10.32	$10.45	$11.08	$11.10	$11.96	$31.76
Tangible Book Value per Share	$7.70	$8.14	$8.94	$9.53	$10.32	$10.45	$11.08	$3.32	$2.93	$2.22
Total Capital	52	56	61	65	71	72	78	78	85	231
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-46	-44	-44	-53	-57	-58	-63	-7.98	-7.21	-9.46
Capital Expenditures (CapEx)	0.49	0.81	0.64	0.30	0.15	-0.74	0.08	-0.03	0.04	-0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.24	-1.04	3.71	-1.16	-0.23	2.41	3.12	9.86	7.95	7.42
Debt-free Net Working Capital (DFNWC)	43	42	47	51	56	60	66	17	15	16
Net Working Capital (NWC)	43	42	47	51	56	60	66	17	15	16
Net Nonoperating Expense (NNE)	-0.11	-0.28	-0.28	-0.37	-0.54	-0.44	-0.64	0.04	-1.15	-26
Net Nonoperating Obligations (NNO)	-46	-44	-44	-53	-57	-58	-64	-7.98	-7.21	-9.46
Total Depreciation and Amortization (D&A)	0.15	0.13	0.13	0.15	0.16	0.16	0.18	0.17	0.13	0.10
Debt-free, Cash-free Net Working Capital to Revenue	-4.12%	-1.83%	6.09%	-1.79%	-0.34%	3.54%	4.73%	15.97%	13.50%	13.19%
Debt-free Net Working Capital to Revenue	79.54%	74.18%	76.67%	78.37%	83.38%	87.62%	100.18%	28.06%	24.87%	29.09%
Net Working Capital to Revenue	79.54%	74.18%	76.67%	78.37%	83.38%	87.62%	100.18%	28.06%	24.87%	29.09%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.55	$0.48	$0.74	$0.88	$0.82	$0.62	$0.88	$0.00	$0.80	$3.98
Adjusted Weighted Average Basic Shares Outstanding	6.68M	6.73M	6.70M	6.71M	6.72M	6.73M	6.89M	6.94M	7.05M	7.23M
Adjusted Diluted Earnings per Share	$0.46	$0.41	$0.63	$0.75	$0.71	$0.54	$0.78	$0.00	$0.72	$3.63
Adjusted Weighted Average Diluted Shares Outstanding	7.94M	8.00M	7.90M	7.87M	7.82M	7.82M	7.78M	7.80M	7.77M	7.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.84M	6.84M	6.85M	6.86M	6.87M	7.03M	7.07M	7.13M	7.27M	9.60M
Normalized Net Operating Profit after Tax (NOPAT)	3.57	2.94	4.69	5.51	5.44	1.76	5.43	3.75	4.46	3.18
Normalized NOPAT Margin	25.40%	21.30%	25.74%	29.60%	33.36%	11.72%	34.17%	25.89%	32.98%	25.58%
Pre Tax Income Margin	32.75%	28.68%	36.43%	41.20%	42.83%	18.68%	49.03%	7.86%	47.18%	262.41%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	39.56%	34.84%	0.00%	22.52%	9.96%	9.47%	0.00%	0.64%	3.69%	7.34%

Financials Breakdown Chart

Key Financial Trends

Semler Scientific (NASDAQ: SMLR) has demonstrated notable financial performance trends over the last four years, with emphasis on the most recent quarters of 2024 and comparison to prior periods.

Revenue and Profitability

Operating revenue increased in Q4 2024 to $12.41 million from $11.65 million in Q4 2023 (calculated by summing Q4 2023 operating revenues, noting a decrease from prior quarters) - indicating a stable revenue base.
Gross profit remains strong, with $11.31 million in Q4 2024, showing operational efficiency despite rising total costs of revenue.
Net income from continuing operations surged significantly to $29.21 million in Q4 2024 from $4.22 million in Q4 2023, mainly due to $29.03 million in other income recognized in Q4 2024, a major impact item boosting profitability.
Basic earnings per share rose sharply to $3.98 in Q4 2024 compared to $0.62 in Q4 2023, reflecting improved profitability on a per-share basis.

Operating Expenses

Selling, General & Admin expenses increased modestly in Q4 2024 ($3.77 million) vs $3.26 million in Q4 2023, showing some upward pressure on overheads.
Marketing expenses decreased to $2.97 million in Q4 2024 from $4.55 million in Q4 2023, which could impact growth or brand-building efforts going forward.
Research & Development expenses are relatively stable but remain significant ($1.03 million in Q4 2024 vs $1.21 million in Q4 2023), critical for innovation investments.

Cash Flows and Liquidity

Net cash from continuing operating activities improved to $7.43 million in Q4 2024 from $4.44 million in Q4 2023, indicating healthy cash generation from core business operations.
Investing activities show heavy outflows ($121.0 million in Q4 2024) largely related to other investing activities; this reflects substantial capital deployment that requires monitoring for future returns.
Financing activities show significant inflows ($115.8 million in Q4 2024) due to common equity issuance, supporting funding for strategic initiatives and investments.
Overall cash and equivalents increased by $2.25 million in Q4 2024, supporting short-term liquidity.

Balance Sheet Strength

Total assets grew steadily from $60.9 million in Q3 2022 to approximately $92.2 million by Q3 2024, driven by growth in intangible assets and investments, indicating strategic asset building.
Shareholders’ equity rose markedly from about $52.4 million in Q3 2022 to $85.4 million by Q3 2024, reflecting retained earnings growth and capital measures.
Current liabilities remain manageable at approximately $6.8 million in Q3 2024, keeping the leverage low and balance sheet healthy.

Shareholder Returns

Earnings per share has grown consistently each year and quarter, with a notable jump in late 2024 signaling improving profitability and potential enhanced shareholder value.
Some repurchases of common equity occurred, but less so in late 2024, possibly reflecting capital allocation to growth rather than buybacks.

Summary

Semler Scientific has posted strong revenue and gross profit growth in recent quarters, with a remarkable increase in net income driven primarily by significant other income in Q4 2024. Operating expenses have been reasonably controlled, though marketing spend has decreased notably. Cash flows from operations have improved, and the company has actively raised capital through issuance of equity to fund large investing initiatives. The balance sheet shows a solid increase in assets and equity with low liabilities, supporting financial stability. Overall, the company is positioned well with improving profitability and liquidity, but investors should watch ongoing investment spending and the sustainability of other income impacts on earnings.

10/14/25 08:45 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Semler Scientific's Financials

When does Semler Scientific's fiscal year end?

According to the most recent income statement we have on file, Semler Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Semler Scientific's net income changed over the last 2 years?

Semler Scientific's net income appears to be on an upward trend, with a most recent value of $40.90 million in 2024, rising from $14.33 million in 2022. The previous period was $20.58 million in 2023. See Semler Scientific's forecast for analyst expectations on what’s next for the company.

What is Semler Scientific's operating income?

Semler Scientific's total operating income in 2024 was $20.93 million, based on the following breakdown:

Total Gross Profit: $51.54 million
Total Operating Expenses: $30.60 million

How has Semler Scientific's revenue changed over the last 2 years?

Over the last 2 years, Semler Scientific's total revenue changed from $56.69 million in 2022 to $56.29 million in 2024, a change of -0.7%.

How much debt does Semler Scientific have?

Semler Scientific's total liabilities were at $9.08 million at the end of 2024, a 44.8% increase from 2023, and a 29.4% increase since 2022.

How much cash does Semler Scientific have?

In the past 2 years, Semler Scientific's cash and equivalents has ranged from $8.82 million in 2024 to $57.20 million in 2023, and is currently $8.82 million as of their latest financial filing in 2024.

How has Semler Scientific's book value per share changed over the last 2 years?

Over the last 2 years, Semler Scientific's book value per share changed from 8.14 in 2022 to 31.76 in 2024, a change of 290.1%.

Related Companies

This page (NASDAQ:SMLR) was last updated on 10/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Semler Scientific (SMLR) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Semler Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Semler Scientific (SMLR) Financials

Annual Income Statements for Semler Scientific

Quarterly Income Statements for Semler Scientific

Annual Cash Flow Statements for Semler Scientific

Quarterly Cash Flow Statements for Semler Scientific

Annual Balance Sheets for Semler Scientific

Quarterly Balance Sheets for Semler Scientific

Annual Metrics And Ratios for Semler Scientific

Quarterly Metrics And Ratios for Semler Scientific

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Semler Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools